SEC Form 4 · accession 0001780851-26-000017
Adaptive Biotechnologies Corp · ADPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harlan S Robins
Officer — Chief Scientific Officer
Period of report
Jul 21, 2026
Accepted (ET)
Jul 23, 2026 · 7:34 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001478320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 21, 2026 | M | 284,800 | $6.55 | A | 1,304,458 | D | |
| Common StockF2 | Jul 21, 2026 | S | 278,698 | $21.72 | D | 1,025,760 | D | |
| Common StockF3 | Jul 21, 2026 | S | 213,702 | $22.12 | D | 812,058 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $6.55 | Jul 21, 2026 | M | 284,800 | D | — | Feb 7, 2028 | Common Stock | 284,800 | 0 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
- F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4The option was fully vested and exercisable.